Assertio Therapeutics

Assertio Therapeutics Overview

Founded 1995
Founded
Status Public
Employees 125
Employees
Stock Symbol ASRT
Stock Symbol
Investments 7
Share Price $0.96 (As of Thursday Closing)

Assertio Therapeutics General Information

Description

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 100 South Saunders Road
  • Suite 300
  • Lake Forest, IL 60045
  • United States
+1 (224) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Assertio Therapeutics Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.96 $0.82 $0.55 - $3.63 $87M 105M 1.33M -$2.23

Assertio Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 368,908 419,692 694,443 1,028,190
Revenue 192,493 229,504 311,770 380,724
EBITDA (29,582) (61,149) 213,282 75,129
Net Income (161,670) (217,201) 36,908 (102,496)
Total Assets 219,274 527,170 932,866 1,038,617
Total Debt 57,866 358,172 566,107 626,730
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Assertio Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Assertio Therapeutics‘s full profile, request access.

Request a free trial

Assertio Therapeutics Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Curemark Accelerator/Incubator Backed Rye Brook, NY 00 000.00 0000000000 000.00
000000000 Formerly VC-backed Rehovot, Israel 00 000.00 000000&0 000.00
000000 00000000000 Formerly VC-backed Ardsley, NY 000 00000 000000&0
00000 000000000000 Formerly VC-backed Bridgewater, NJ 0000 00000 000000&0

Assertio Therapeutics Executive Team (23)

Name Title Board Seat Contact Info
Arthur Higgins Chief Executive Officer & Board Member
Daniel Peisert Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Stanley Bukofzer MD Chief Scientific Officer & Chief Technology Officer, Technology
Vince Anido Ph.D Director
John Thomas Senior Vice President, Investor Relations and Corporate Communications

18 Former Executives

Assertio Therapeutics Board Members (11)

To view Assertio Therapeutics‘s full board member team, request access >>
Name Representing Role Since
Arthur Higgins Assertio Therapeutics Chief Executive Officer & Board Member 000 0000
G. Steven Burrill Self Board Member 000 0000
Heather Mason Assertio Therapeutics Board Member 000 0000
James Fogarty Assertio Therapeutics Chairman & Board Member 000 0000
James Tyree Self Board Member 000 0000

3 Former Board Members

Assertio Therapeutics Investments & Acquisitions (7)

To view Assertio Therapeutics‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 0000 00000000 20-May-2020 000000000000000000 Drug Delivery 00000 000000
00á0 000000000 000 07-Nov-2017 000000000 00000 00 Other Healthcare
0000000 0000000000 02-Apr-2015 000000000 00000 00 00.000 Buildings and Property 00000 000000000
00000000 000000000 31-Dec-2013 000000000000000000 000.00 Drug Discovery
Kowa Pharmaceuticals America (Diclofenac Products) 17-Dec-2013 Corporate Asset Purchase 000.00 Drug Discovery

Assertio Therapeutics Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 02-Apr-2015 000000000 00000 00 00.000 Completed
  • 00000000 000000000
Depomed (Lazanda nasal spray) 29-Jul-2013 Corporate Asset Purchase 000 Completed